APOE and familial hyperaldosteronism: Although LDLR is the logical transgene to use for gene therapy of FH, we and others have considered an alternative approach using the gene encoding the very-low-density lipoprotein receptor (VLDLR) which is a member of the LDLR super family that binds with high affinity to APOE containing lipoproteins such as VLDL [14], [17].